MedPath

The Effectiveness of Idazoxan in Treating TRD

Phase 3
Withdrawn
Conditions
Major Depressive Disorder
Registration Number
NCT00294944
Lead Sponsor
Sheba Medical Center
Brief Summary

Assessing the effectiveness of Idazoxan as a treatment for depressive patients who did not respond to treatment with SSRI

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • MDD patients
  • Did not respond to at least one treatment of 4-6 weeks of SSRI in adequate dose
  • In or out patients
Exclusion Criteria
  • Psychotic symptoms

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chaim Sheba Medical Center

🇮🇱

Ramat-Gan, Israel

© Copyright 2025. All Rights Reserved by MedPath